Business
Submission for Bioavailability and Efficacy Trial
Submission for Bioavailability and Efficacy Trial.
About this update from Kanabo Group Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 7528U\n Kanabo Group PLC\n 07 December 2021\n \n \n \n \n Kanabo Group Plc\n \n \n (\"Kanabo\" or the \"Company\")\n \n \n Submission for Medical Bioavailability and Efficacy Trial\n \n \n Bioavailability and Efficacy Trial to Commence using VapePod\n \n \n Kanabo Group Plc (LSE:KNB), a medical cannabis and R&D Company that focuses on the distribution of cannabis-derived products for medical patients and wellness CBD consumers, announces it has applied to undertake a bioavailability and efficacy trial (the \"Trial\") of its proprietary Cannabis inhalation formulas used in conjunction with its VapePod delivery device.\n \n \n \n \n \n The outcome of this 3-month trial will be:\n \n \n \n \n \n 1. An approval to sell the medical vape and formulas in Israel - this will be the first cannabis vape cartridges in the Israeli market.\n \n \n \n \n \n 2. To support sales in UK and Germany by providing physicians and the medical establishments with evidence-based medicine.\n \n \n \n \n \n 3. This is expected to be the first clinical trial for a cannabis vape pen in the world, that will provide bioavailability and efficacy data.\n \n \n \n \n \n Kanabo, in partnership with Seach Medical Group, has submitted a clinical trial protocol for approval at the Hadassah Medical Centre and subsequent review by the Helsinki Committee to test the impact from the inhalation of various Cannabis formulas via its proprietary VapePod delivery device, which dispenses standardised and metered inhalations, on healthy volunteers. \n \n \n \n \n \n As part of the Trial, participants will undertake a pharmacokinetic (\"PK\") analysis to define THC and CBD Absorption, Distribution, Metabolism and Excretion (\"ADME\") following the administration of the Company's proprietary VapePod Formulas.\n \n \n \n \n \n Once successfully completed, the Trial will help Kanabo target the rapidly growing segments of the medicinal Cannabis market for patients who wish to manage their pain using a clean and measurable method of treatment.\n \n \n \n \n \n \n \n \n \n \n Avihu Tamir, Kanabo's CEO commented\n \n : \"\n \n \n This is a ground-breaking trial which will evaluate the bioavailability and efficacy of Cannabis-based inhalation formulas administered via Kanabo's VapePod medical device...